Information Provided By: 
Fly News Breaks for August 17, 2018
ESPR
Aug 17, 2018 | 08:17 EDT
As previously reported, Citi analyst Joel Beatty upgraded Esperion to Buy from Neutral because he believes bempedoic acid for LDL-lowering is likely to be approved. His 70% probability of approval view is higher than the roughly 40% odds of success he believes is currently priced in the stock, Beatty tells investors. His increased price target of $75, up from $57 previously, assumes $1.2B in bempedoic acid sales in 2025, Beatty noted.
News For ESPR From the Last 2 Days
There are no results for your query ESPR
